In a recent survey we asked for your feedback about the BNF eNewsletter, and in response to your comments we have redesigned the June edition. We hope you’ll find it clearer, more succinct and easier to find the information you need. Let us know what you think at email@example.com.
This month’s issue contains a useful case study on managing chronic asthma, along with the latest guidance and content updates to the BNF and BNFC.
Previous newsletters can be found below:
In the print editions of BNF Publications, where there is common information relating to a class of drugs, the shared properties are contained in a drug-class monograph. Drug-class monographs are highlighted by a circled flag symbol beside the title of the drug-class monograph. The corresponding individual drug monographs usually follow the drug-class monograph, and are highlighted by a non-circled flag symbol.
For example, the monograph for atenolol will display a flag, indicating that the drug-class monograph for Beta-adrenoceptor blockers (systemic), should be consulted in tandem. For more information, see How to use BNF publications in print in the preface of the current print publications.
The “clarifications and corrections” page that was set up for BNF 70 has now been retired and you will find all future clarifications and corrections on the clinical news page.
A joint statement from UKMi, the Neonatal and Paediatrics Pharmacy Group (NPPG) and the BNF: